Henan Lingrui Pharmaceutical and its subsidiaries are engaged in the manufacture and distribution of medicines, health care products and medical equipment; research and development of new products and new technology; provision of technical services; export of self-produced products and related technologies; import of raw materials, materials for experiment, machinery and equipment, instruments and meters, spare parts and other related technologies; provision of information services; and investment in real estate, cultural education, advertising and hotel.
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
A director at Henan Lingrui Pharmaceutical sold 583,800 shares at 10.553CNY and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The...
Feasibility Study Results in December to be a Catalyst for this Junior
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...
The independent financial analyst theScreener just lowered the general evaluation of MULTICHOICE GROUP LTD. (ZA), active in the Broadcasting & Entertainment industry. As regards its fundamental valuation, the title still shows 1 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as moderately risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Neutral. As of the analysis date February 21, 2020, the closing price was ZAR 99.80 and its target price was estimated at ZAR 94.04.
The general evaluation of TRUWORTHS INTL.LTD. (ZA), a company active in the Apparel Retailers industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date February 21, 2020, the closing price was ZAR 48.50 and its potential was estimated at ZAR 52.74.
The independent financial analyst theScreener just lowered the general evaluation of NETCARE LTD. (ZA), active in the Health Care Providers industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date February 21, 2020, the closing price was ZAR 19.40 and its target price was estimated at ZAR 16.95.